Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR'HIV): a multicenter, international, non-randomized clinical trial study protocol

DISCUSSION: The SHINGR'HIV trial will provide robust data on the immunogenicity and safety profile of RZV in older PLWH to support vaccination guidelines in this population.TRIAL REGISTRATION: ClinicalTrials.gov NCT05575830. Registered on 12 October 2022. Eu Clinical Trial Register (EUCT number 2023-504482-23-00).PMID:38504173 | DOI:10.1186/s12879-024-09192-5

Source: Herpes - March 20, 2024 Category: Infectious Diseases Authors: Maxime Hentzien Fabrice Bonnet Enos Bernasconi Emmanuel Biver Dominique L Braun Aline Munting Karoline Leuzinger Olivier Leleux Stefano Musardo Virginie Prendki Patrick Schmid Cornelia Staehelin Marcel Stoeckle Carla S Walti Linda Wittkop Victor Appay Arn Source Type: research